What FDA Approves Cosentyx For
Cosentyx (secukinumab) treats plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa in adults and children aged 2 and older for some indications.[1]
How Cosentyx Works
It blocks interleukin-17A (IL-17A), a protein driving inflammation in autoimmune conditions like psoriasis and arthritis.[1]
Common Uses in Practice
Doctors prescribe it most for moderate-to-severe plaque psoriasis unresponsive to other treatments, psoriatic arthritis with skin and joint symptoms, and axial spondyloarthritis causing back pain.[1]
Who Cannot Use Cosentyx
Avoid in active inflammatory bowel disease or Crohn's disease history, as it worsens these. Not for use with live vaccines.[1]
Dosage and Administration
Subcutaneous injection: 300 mg weekly for 5 weeks, then monthly for psoriasis; 150-300 mg monthly for arthritis based on weight and response.[1]
Side Effects Patients Report
Infections (upper respiratory, candida), diarrhea, injection site reactions. Serious risks include inflammatory bowel disease flare-ups and allergic reactions.[1]
How Cosentyx Compares to Humira or Stelara
Cosentyx targets only IL-17A, differing from Humira's TNF inhibition or Stelara's IL-12/23 blockade. Trials show similar efficacy for psoriasis clearance but faster joint improvement in psoriatic arthritis.[1]
When Does Cosentyx Patent Expire
Key U.S. patents expire between 2030-2034; biosimilars unlikely before then amid ongoing litigation.[2]
[1] https://www.cosentyx.com
[2] https://www.drugpatentwatch.com/p/tradename/COSENTYX